Virtus ETF Advisers’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Virtus ETF Advisers’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,575	Closed	-$424K	–	501
2022 Q1	$424K	Hold	3,575	–	–	0.19%	148
2021 Q4	$493K	Sell	3,575 -983	-22%	-$125K	0.19%	117
2021 Q3	$633K	Sell	4,558 -415	-8%	-$51.8K	0.28%	111
2021 Q2	$483K	Sell	4,973 -2,220	-31%	-$180K	0.2%	160
2021 Q1	$492K	Buy	7,193 +196	+3%	+$15.9K	0.21%	150
2020 Q4	$600K	Buy	6,997 +2,326	+50%	+$197K	0.25%	114
2020 Q3	$304K	Sell	4,671 -647	-12%	-$42.4K	0.16%	221
2020 Q2	$389K	Sell	5,318 -1,539	-22%	-$81.9K	0.18%	211
2020 Q1	$233K	Sell	6,857 -1,003	-13%	-$45.9K	0.1%	263
2019 Q4	$428K	Buy	7,860 +3,834	+95%	+$190K	0.07%	236
2019 Q3	$168K	Sell	4,026 -223	-5%	-$9.42K	0.03%	272
2019 Q2	$186K	Sell	4,249 -3,160	-43%	-$178K	0.04%	285
2019 Q1	$381K	Sell	7,409 -911	-11%	-$39.4K	0.81%	38
2018 Q4	$308K	Sell	8,320 -3,305	-28%	-$119K	0.05%	106
2018 Q3	$437K	Sell	11,625 -8,529	-42%	-$314K	0.05%	147
2018 Q2	$796K	Buy	+20,154	New	+$639K	0.7%	31

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Virtus ETF Advisers's BHVN Position: Q2 2022 in Review

Virtus ETF Advisers sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 3,575 shares — an estimated $424K sold.

Virtus ETF Advisers first reported a position in BHVN in Q2 2018 and held it in 16 quarters. The position peaked at $796K in Q2 2018. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Virtus ETF Advisers reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 3,575 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $424K.
Virtus ETF Advisers first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2018 and held it in 16 quarters.
Virtus ETF Advisers's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $796K in Q2 2018.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.